WHO/BS/2019.2372 WHO 1st IS for antiserum to RSV

Overview

A collaborative study was conducted with the aim to expand the use of the 1st International Standard for antiserum to RSV (16/284) to include RSV neutralisation titres against RSV/B. The study included 11 laboratories from 6 countries, representing university laboratories, manufacturers/developers of RSV vaccines and public health laboratories. All participants used their own in-house virus neutralization assay and their own virus stocks. The study samples comprised the current international standard (16/284) and its potential replacement (16/322), individual sera from naturally infected humans, a monoclonal antibody to RSV (palivizumab) and samples from the BEI Resources panel of human antiserum and immune globulin to RSV. Of the 11 laboratories that took part in the study, 5 returned data from neutralisation assays with and without the inclusion of serum complement.